{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:17:52Z","timestamp":1775672272443,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Oral targeted agents are desirable for treatment of Kaposi sarcoma (KS); however, in patients with HIV, drug\u2013drug interactions must be considered. In this study to treat KS, sorafenib was poorly tolerated at doses less than those approved by the U.S. Food and Drug Administration for hepatocellular carcinoma and other cancers, and showed only modest activity. Sorafenib's metabolism occurs via the CYP3A4 pathway, which is inhibited by ritonavir, a commonly used antiretroviral agent used by most patients in this study. Strong CYP3A4 inhibition by ritonavir may contribute to the observed sorafenib toxicity. Alternate antiretroviral agents without predicted interactions are preferred for co-administration in patients with HIV and cancers for which sorafenib is indicated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We conducted a phase Ib study of sorafenib, a vascular epithelial growth factor receptor (VEGFR), c-kit, and platelet derived growth factor receptor (PDGFR)-targeted treatment in Kaposi sarcoma (KS). We evaluated drug\u2013drug interactions between sorafenib and ritonavir, an HIV medication with strong CYP3A4 inhibitory activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Two cohorts were enrolled: HIV-related KS on ritonavir (Cohort R) and HIV-related or classical KS not receiving ritonavir (Cohort NR). Sorafenib dose level 1 in cohort R (R1) was 200 mg daily and 200 mg every 12 hours in cohort NR (NR1). Steady-state pharmacokinetics were evaluated at cycle 1, day 8. KS responses and correlative factors were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten patients (nine HIV+) were enrolled: R1 (eight), NR1 (two). Median CD4+ count (HIV+) was 500 cells\/\u00b5L. Dose-limiting toxicities (DLTs) were grade 3 elevated lipase (R1), grade 4 thrombocytopenia (R1), and grade 3 hand-foot syndrome (NR1). Two of seven evaluable patients had a partial response (PR; 29%; 95% CI 4%\u201371%). Steady-state area under the curve of the dosing interval (AUCTAU) of sorafenib was not significantly affected by ritonavir; however, a trend for decreased AUCTAU of the CYP3A4 metabolite sorafenib-N-oxide (3.8-fold decrease; p\u2009=\u2009.08) suggests other metabolites may be increased.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Sorafenib was poorly tolerated, and anti-KS activity was modest. Strong CYP3A4 inhibitors may contribute to sorafenib toxicity, and ritonavir has previously been shown to be a CYP3A4 inhibitor. Alternate antiretroviral agents without predicted interactions should be used when possible for concurrent administration with sorafenib.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0486","type":"journal-article","created":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T01:19:02Z","timestamp":1490404742000},"page":"505-e49","source":"Crossref","is-referenced-by-count":26,"title":["A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma"],"prefix":"10.1093","volume":"22","author":[{"given":"Thomas S.","family":"Uldrick","sequence":"first","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila H.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Wyvill","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody J.","family":"Peer","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Bernstein","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Aleman","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark N.","family":"Polizzotto","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Venzon","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section at the Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section at the Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vickie","family":"Marshall","sequence":"additional","affiliation":[{"name":"Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Whitby","sequence":"additional","affiliation":[{"name":"Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[{"name":"Analytical Pharmacology Core, Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"key":"2021122507535709400_onco12076-bib-0001","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1073\/pnas.1010693107","article-title":"Structure and mechanism of the complex between cytochrome p4503a4 and ritonavir","volume":"107","author":"Sevrioukova","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122507535709400_onco12076-bib-0002","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0091270011404027","article-title":"Phase I trial of sorafenib in combination with 5-fluorouracil\/leucovorin in advanced solid tumors","volume":"52","author":"Shacham-Shmueli","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2021122507535709400_onco12076-bib-0003","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.bjc.6605777","article-title":"A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer","volume":"103","author":"Desar","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122507535709400_onco12076-bib-0004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10637-012-9820-z","article-title":"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer","volume":"31","author":"Azad","year":"2013","journal-title":"Invest New Drugs"},{"key":"2021122507535709400_onco12076-bib-0005","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1a1 but is metabolized by UGT1a9: Implications of genetic variants on pharmacokinetics and hyperbilirubinemia","volume":"18","author":"Peer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122507535709400_onco12076-bib-0006","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200544020-00001","article-title":"Interactions between antiretrovirals and antineoplastic drug therapy","volume":"44","author":"Antoniou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2021122507535709400_onco12076-bib-0007","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.28554","article-title":"A phase 1\/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS malignancy consortium trial AMC 061","volume":"120","author":"Rudek","year":"2014","journal-title":"Cancer"},{"key":"2021122507535709400_onco12076-bib-0008","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","article-title":"Lack of effect of ketoconazole-mediated CYP3a inhibition on sorafenib clinical pharmacokinetics","volume":"57","author":"Lathia","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122507535709400_onco12076-bib-0009","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","article-title":"Sorafenib: A review of its use in advanced hepatocellular carcinoma","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"key":"2021122507535709400_onco12076-bib-0010","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1200\/JOP.2014.002709","article-title":"Cancer treatment in patients with HIV infection and non-AIDS-defining cancers: A survey of US oncologists","volume":"11","author":"Suneja","year":"2015","journal-title":"J Oncol Pract"},{"key":"2021122507535709400_onco12076-bib-0011","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"key":"2021122507535709400_onco12076-bib-0012","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nm0896-925","article-title":"KSHV antibodies among Americans, Italians, and Ugandans with and without Kaposi's sarcoma","volume":"2","author":"Gao","year":"1996","journal-title":"Nat Med"},{"key":"2021122507535709400_onco12076-bib-0013","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/jnci\/djm010","article-title":"AIDS-related cancer and severity of immunosuppression in persons with AIDS","volume":"99","author":"Biggar","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122507535709400_onco12076-bib-0014","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.23487","article-title":"Cancer risk in people infected with human immunodeficiency virus in the United States","volume":"123","author":"Engels","year":"2008","journal-title":"Int J Cancer"},{"key":"2021122507535709400_onco12076-bib-0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021122507535709400_onco12076-bib-0016","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1258\/ijsa.2008.008372","article-title":"Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983\u20132006)","volume":"20","author":"Mosam","year":"2009","journal-title":"Int J STD AIDS"},{"key":"2021122507535709400_onco12076-bib-0017","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1523-1747.1999.00798.x","article-title":"Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma","volume":"113","author":"Skobe","year":"1999","journal-title":"J Invest Dermatol"},{"key":"2021122507535709400_onco12076-bib-0018","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/371674a0","article-title":"Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma","volume":"371","author":"Ensoli","year":"1994","journal-title":"Nature"},{"key":"2021122507535709400_onco12076-bib-0019","doi-asserted-by":"crossref","first-page":"27617","DOI":"10.1074\/jbc.274.39.27617","article-title":"Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells","volume":"274","author":"Marchi\u00f2","year":"1999","journal-title":"J Biol Chem"},{"key":"2021122507535709400_onco12076-bib-0020","first-page":"2007","article-title":"Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: A combined in vitro and in vivo analysis","volume":"10","author":"St\u00fcrzl","year":"1995","journal-title":"Oncogene"},{"key":"2021122507535709400_onco12076-bib-0021","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2012.48.6365","article-title":"Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042","volume":"10","author":"Koon","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122507535709400_onco12076-bib-0022","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1073\/pnas.94.3.979","article-title":"Vascular endothelial growth factor\/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma","volume":"94","author":"Masood","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122507535709400_onco12076-bib-0023","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2007.14.5532","article-title":"Including persons with HIV infection in cancer clinical trials","volume":"26","author":"Persad","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122507535709400_onco12076-bib-0024","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122507535709400_onco12076-bib-0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2007.11.009","article-title":"Viral hepatitis and HIV coinfection","volume":"48","author":"Sulkowski","year":"2008","journal-title":"J Hepatol"},{"key":"2021122507535709400_onco12076-bib-0026","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/hiv.12204","article-title":"Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: The Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalit\u00e9 2010 survey","volume":"16","author":"Rosenthal","year":"2015","journal-title":"HIV Med"},{"key":"2021122507535709400_onco12076-bib-0027","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1007\/s12032-010-9669-y","article-title":"Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART? A case report","volume":"28(suppl 1)","author":"Chelis","year":"2011","journal-title":"Med Oncol"},{"key":"2021122507535709400_onco12076-bib-0028","first-page":"161","article-title":"Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: A case report","volume":"58","author":"Ozenne","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"2021122507535709400_onco12076-bib-0029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CAD.0b013e32835c032f","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients","volume":"24","author":"Berretta","year":"2013","journal-title":"Anticancer Drugs"},{"key":"2021122507535709400_onco12076-bib-0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-9378-7-15","article-title":"Treatment of recurrent hepatocellular carcinoma with sorafenib in a HIV\/HCV co-infected patient in HAART: A case report. Infect","volume":"7","author":"Nardo","year":"2012","journal-title":"Agent Cancer"},{"key":"2021122507535709400_onco12076-bib-0031","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1634\/theoncologist.2010-0010","article-title":"Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: A case report","volume":"15","author":"Perboni","year":"2010","journal-title":"The Oncologist"},{"key":"2021122507535709400_onco12076-bib-0032","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2011.39.6853","article-title":"Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy","volume":"30","author":"Uldrick","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122507535709400_onco12076-bib-0033","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1099\/vir.0.006239-0","article-title":"Cytokine production by human herpesvirus 8-infected dendritic cells","volume":"90","author":"Hensler","year":"2009","journal-title":"J Gen Virol"},{"key":"2021122507535709400_onco12076-bib-0034","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1128\/JVI.01769-06","article-title":"Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells","volume":"81","author":"Punjabi","year":"2007","journal-title":"J Virol"},{"key":"2021122507535709400_onco12076-bib-0035","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1038\/srep04241","article-title":"STAT3 activation by KSHV correlates with IL-10, IL-6 and IL-23 release and an autophagic block in dendritic cells","volume":"4","author":"Santarelli","year":"2014","journal-title":"Sci Rep"},{"key":"2021122507535709400_onco12076-bib-0036","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.2011.396","article-title":"Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980\u20132007","volume":"305","author":"Shiels","year":"2011","journal-title":"JAMA"},{"key":"2021122507535709400_onco12076-bib-0037","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2002-07-2130","article-title":"Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma","volume":"101","author":"Aoki","year":"2003","journal-title":"Blood"},{"key":"2021122507535709400_onco12076-bib-0038","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-10-2331","article-title":"Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib","volume":"17","author":"Kelly","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122507535709400_onco12076-bib-0039","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1158\/1535-7163.MCT-11-0813","article-title":"A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts","volume":"11","author":"Wang","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2021122507535709400_onco12076-bib-0040","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000335472","article-title":"Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma","volume":"81","author":"Cheng","year":"2011","journal-title":"Oncology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0486","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/5\/505\/41915872\/oncolo_22_5_505.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/5\/505\/41915872\/oncolo_22_5_505.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:55:28Z","timestamp":1640418928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/5\/505\/6438962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,3,24]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0486","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,1]]},"published":{"date-parts":[[2017,3,24]]}}}